The expansion of the partnership between Gilead Sciences, Inc.’s Kite Pharma division and Arcellx, Inc. to include an additional multiple myeloma program as well as lymphomas brings Arcellx additional cash while also providing a potential competitive advantage to the BCMA-directed CAR-T cell therapy program that is the partnership’s focus.
The two companies announced the expanded deal on 15 November, with Kite exercising an option for Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma and expanding the existing terms around CART-ddBCMA to include lymphomas
Key Takeaways
-
Gilead and Arcellx expanded their partnership first announced in December 2022 to include an additional anti-BCMA program and to develop CART-ddBCMA for lymphomas.
-
Arcellx will receive an additional $285m, on top of the original deal’s potentially more than $4bn value
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?